MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3 Retraction in /10.3892/mmr.2022.12857

Liu,Nian; Liu,Zhiguang; Zhang,Weidong; Li,Yang; Cao,Jun; Yang,Huan; Li,Xiuying

doi:10.3892/mmr.2018.9020

MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3

Retraction in: /10.3892/mmr.2022.12857

Authors:
- Nian Liu
- Zhiguang Liu
- Weidong Zhang
- Yang Li
- Jun Cao
- Huan Yang
- Xiuying Li
View Affiliations

Affiliations: Department of Respiration, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China, Department of Integrated Traditional Chinese and Western Medicine, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: May 14, 2018 https://doi.org/10.3892/mmr.2018.9020
Pages: 1155-1164

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNA/miRs) have been associated with the initiation and progression of non‑small‑cell lung cancer (NSCLC). Hence, a comprehensive understanding of the association between dysregulated miRNAs and NSCLC may contribute to the identification of novel therapeutic methods for patients with NSCLC. MiRNA‑433 (miR‑433) has been reported to be dysregulated in numerous types of human cancers; however, its expression pattern, biological roles and associated mechanisms in NSCLC require further investigation. The present study aimed to detect miR‑433 expression and determine its roles and underlying molecular mechanisms in NSCLC. In the present study, reverse transcription‑quantitative polymerase chain reaction revealed that miR‑433 was significantly downregulated in NSCLC tissues and cell lines. This decreased miR‑433 expression was strongly associated with the tumor node metastasis stage and lymph node metastasis of patients with NSCLC. Cell Counting kit‑8 and cell invasion assays revealed that the resumption of miR‑433 expression decreased the proliferation and invasion of NSCLC cells. Bioinformatics analysis predicted E2F transcription factor 3 (E2F3) as a potential target of miR‑433. Luciferase reporter assay, RT‑qPCR and western blot analysis further demonstrated that E2F3 was a direct target of miR‑433 in NSCLC. E2F3 downregulation induced by small interfering RNA exhibited inhibitory effects similar to those of miR‑433 overexpression in NSCLC cells, and the restored E2F3 expression counteracted the suppressive effects on NSCLC cells induced by miR‑433 overexpression. Therefore, miR‑433 may inhibit the progression of NSCLC, at least in part, by targeting E2F3. The present study indicated that miR‑433 may be investigated as an innovative candidate target for the therapy of patients with this fatal disease.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 5 Suppl 4:S389–S396. 2013.PubMed/NCBI
4	Li X, Shi Y, Yin Z, Xue X and Zhou B: An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma. J Transl Med. 12:1592014. View Article : Google Scholar : PubMed/NCBI
5	Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S, Goto K, Ohmatsu H, Saijo N and Nishiwaki Y: Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol. 3:617–622. 2008. View Article : Google Scholar : PubMed/NCBI
6	Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, Mok T, Rosell R and Klughammer B: Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: Pooled analysis. J Cell Mol Med. 14:51–69. 2010. View Article : Google Scholar : PubMed/NCBI
7	Fassina A, Cappellesso R and Fassan M: Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest. 140:1305–1311. 2011. View Article : Google Scholar : PubMed/NCBI
8	Simon J: Technology radiation technology targets tumors. Surgical precision without the incision. S D Med. 67:3622014.PubMed/NCBI
9	Johtatsu T, Noguchi S, Yatera K, Shinohara S, Oka S, Yamasaki K, Nishida C, Kawanami T, Kawanami Y, Ishimoto H, et al: A case of lung adenocarcinoma with uncontrollable myocardial metastasis and pericardial effusion. J UOEH. 36:199–203. 2014.(In Japanese). View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Wilson RC and Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013. View Article : Google Scholar : PubMed/NCBI
12	Berezikov E, van Tetering G, Verheul M, van de Belt J, van Laake L, Vos J, Verloop R, van de Wetering M, Guryev V, Takada S, et al: Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. Genome Res. 16:1289–1298. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
14	Fadejeva I, Olschewski H and Hrzenjak A: MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
15	Lü L, Mao X, Shi P, He B, Xu K, Zhang S and Wang J: MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 96:e70852017. View Article : Google Scholar : PubMed/NCBI
16	Ahir BK, Ozer H, Engelhard HH and Lakka SS: MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review. Crit Rev Oncol Hematol. 120:22–33. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
18	Cortés-Sempere M and de Cáceres Ibáñez I: microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol. 13:357–362. 2011. View Article : Google Scholar : PubMed/NCBI
19	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
20	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
21	Guo LH, Li H, Wang F, Yu J and He JS: The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
22	Li J, Mao X, Wang X, Miao G and Li J: miR-433 reduces cell viability and promotes cell apoptosis by regulating MACC1 in colorectal cancer. Oncol Lett. 13:81–88. 2017. View Article : Google Scholar : PubMed/NCBI
23	Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP and Liu LY: MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4). Mol Cell Biochem. 399:77–86. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yang Z, Tsuchiya H, Zhang Y, Hartnett ME and Wang L: MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. J Biol Chem. 288:28893–28899. 2013. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Al Ahmed HA and Nada O: E2F3 transcription factor: A promising biomarker in lung cancer. Cancer Biomark. 19:21–26. 2017. View Article : Google Scholar : PubMed/NCBI
27	Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, et al: Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer. 54:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
28	Ren J, Ding L, Xu Q, Shi G, Li X, Li X, Ji J, Zhang D, Wang Y, Wang T and Hou Y: LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway. Sci Rep. 7:7492017. View Article : Google Scholar : PubMed/NCBI
29	Zhang J, Li Y, Dong M and Wu D: Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer. Oncol Lett. 14:4983–4988. 2017. View Article : Google Scholar : PubMed/NCBI
30	Trikha P, Sharma N, Pena C, Reyes A, Pécot T, Khurshid S, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, et al: E2f3 in tumor macrophages promotes lung metastasis. Oncogene. 35:3636–3646. 2016. View Article : Google Scholar : PubMed/NCBI
31	Zhao D, Han W, Liu X, Cui D and Chen Y: MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2. Thorac Cancer. 8:304–311. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zhao X, Lu C, Chu W, Zhang B, Zhen Q, Wang R, Zhang Y, Li Z, Lv B, Li H and Liu J: MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII. Tumour Biol. 39:10104283177062152017. View Article : Google Scholar : PubMed/NCBI
33	Castro D, Moreira M, Gouveia AM, Pozza DH and De Mello RA: MicroRNAs in lung cancer. Oncotarget. 8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
34	Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R and Licht JD: miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 27:344–352. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wang XC, Ma Y, Meng PS, Han JL, Yu HY and Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682. 2015. View Article : Google Scholar : PubMed/NCBI
36	Liang T, Guo Q, Li L, Cheng Y, Ren C and Zhang G: MicroRNA-433 inhibits migration and invasion of ovarian cancer cells via targeting Notch1. Neoplasma. 63:696–704. 2016. View Article : Google Scholar : PubMed/NCBI
37	Li X, Yang L, Shuai T, Piao T and Wang R: MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016. View Article : Google Scholar : PubMed/NCBI
38	Sun S, Wang X, Xu X, Di H, Du J, Xu B, Wang Q and Wang J: MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget. 8:5057–5068. 2017.PubMed/NCBI
39	Sun Y, Wang F, Wang L, Jiao Z, Fang J and Li J: MicroRNA-433 regulates apoptosis by targeting PDCD4 in human osteosarcoma cells. Oncol Lett. 14:2353–2358. 2017. View Article : Google Scholar : PubMed/NCBI
40	Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S and Cooper CS: Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene. 26:1028–1037. 2007. View Article : Google Scholar : PubMed/NCBI
41	Guo Y, Qi Y, Guo A, Du C, Zhang R and Chu X: miR-564 is downregulated in gastric carcinoma and targets E2F3. Oncol Lett. 13:4155–4160. 2017. View Article : Google Scholar : PubMed/NCBI
42	Chang SW, Yue J, Wang BC and Zhang XL: miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol. 8:12853–12860. 2015.PubMed/NCBI
43	Lee M, Oprea-Ilies G and Saavedra HI: Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis. Oncotarget. 6:37316–37334. 2015. View Article : Google Scholar : PubMed/NCBI
44	Wang JP, Jiao Y, Wang CY, Xu ZB and Zhang B: Rb knockdown accelerates bladder cancer progression through E2F3 activation. Int J Oncol. 50:149–160. 2017. View Article : Google Scholar : PubMed/NCBI
45	Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ and Sauter G: E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 23:5616–5623. 2004. View Article : Google Scholar : PubMed/NCBI
46	Dong D, Gong Y, Zhang D, Bao H and Gu G: miR-874 suppresses the proliferation and metastasis of osteosarcoma by targeting E2F3. Tumour Biol. 37:6447–6455. 2016. View Article : Google Scholar : PubMed/NCBI